MedPath

Physical Therapy Trial for Pelvic Pain

Not Applicable
Completed
Conditions
Chronic Prostatitis
Chronic Pelvic Pain Syndrome
Interstitial Cystitis
Painful Bladder Syndrome
Interventions
Other: Global Therapeutic Massage (GTM)
Other: Myofascial physical therapy (MPT)
Registration Number
NCT00434343
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brief Summary

The purpose of this study is to determine if a randomized trial of physical therapy for pelvic pain is feasible.

Detailed Description

This is a pilot study wherein eligible participants will be randomly assigned to receive either myofascial tissue manipulation or global therapeutic massage. Those receiving myofascial tissue manipulation will have targeted internal and external connective tissue manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen. Those receiving global therapeutic massage will have non-specific somatic treatment with full-body Western massage.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
47
Inclusion Criteria
  • female and male patients who have failed to respond to previous therapies for interstitial cystitis/painful bladder syndrome
  • male patients who have failed to respond to previous therapies for chronic prostatitis/chronic pelvic pain syndrome
Exclusion Criteria
  • neurologic disorder affecting bladder
  • bladder cancer, prostate cancer, or urethral cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Global Therapeutic Massage (GTM)Global Therapeutic Massage (GTM)Weekly massages consisting of full body Western massage for 1hour.
Myofascial physical therapy (MPT)Myofascial physical therapy (MPT)Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
Primary Outcome Measures
NameTimeMethod
Number consenting to join study out of eligible patients approached6 months

This study will recruit both female and male patients who have failed to respond to previous therapies for either Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) or male patients who have failed to respond to previous therapies for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).

Number of times therapists adhered to prescribed therapeutic protocol12 weeks

For each therapy session therapy records are reviewed to determine whether the therapist followed the therapeutic protocol. Each therapy session is scored as adherent or non-adherent and the number of adherent sessions are recorded per participant

Secondary Outcome Measures
NameTimeMethod
Global response assessment (GRA) Global response assessment12 weeks

The global response assessment consists of the following question: "As compared to when you started the study, how would you rate your overall symptoms now?" 1. markedly worse, 2. moderately worse, 3. slightly worse, 4. the same, 5. slightly improved, 6. moderately improved, 7. markedly improved

Tolerability of treatment measured by number of treatment sessions participants completed12 weeks

Treatment session completion was tracked and used to measure tolerability of treatment.

Number of adverse events reported by the participants12 weeks

Number of adverse events reported by the participants

Trial Locations

Locations (5)

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Northwestern University Feinberg School of Medicine

🇺🇸

Chicago, Illinois, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

William Beaumont Hospital

🇺🇸

Royal Oak, Michigan, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath